Pharmaceutical methods and topical compositions containing acitretin
AssigneeDouglas Pharmaceuticals Limited
InventorsPeter Surman, Fergus Cameron Binnie, Marten Geert Vos
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis.
Claims45
A topical medicament for reducing at least one symptom of at least one dermatological condition comprising acitretin as a nanosuspension.
A topical medicament for reducing at least one symptom of at least one dermatological condition comprising not less than 0.25% w/w acitretin, wherein the medicament shows a release rate of not less than 0.01 mg/cm2 per min1/2 as measured using a Franz diffusion cell in vitro release testing system utilizing the following conditions:
- receptor medium comprising 1% DMSO in (35% ethanol:
- 65% phosphate buffer pH 8.0), speed 700 rpm, membrane polysulfone 0.45 μm, dosage 300±30 mg, temperature 32.5±0.5° C.
18-19. (canceled)
A topical medicament for reducing at least one symptom of at least one dermatological condition comprising at least about 0.5% w/w acitretin, wherein the medicament shows a release rate of not less than 0.01 mg/cm2 per min1/2 as measured using a Franz diffusion cell in vitro release testing system utilizing the following conditions:
- receptor medium comprising 1% DMSO in (35% ethanol:
- 65% phosphate buffer pH 8.0), speed 700 rpm, membrane polysulfone 0.45 μm, dosage 300±30 mg, temperature 32.5±0.5° C.
A topical medicament for reducing at least one symptom of at least one dermatological condition comprising acitretin particles as a nanosuspension, wherein at least 90%, by volume, of the acitretin particles suspended are 1 micron or less in size.
46-66. (canceled)
Dependencies are inferred from the claim text.